Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Co-Developed Drugs Deliver Early Synergistic Results Without Added Toxicities

This article was originally published in The Pink Sheet Daily

Executive Summary

One + one turned into a possible three when Genentech drugs targeting PI3K and MEK were combined in an early solid tumor study reported at the American Association for Cancer Research meeting April 2.

You may also be interested in...



Can “Novel-Novel” Drug Development Work? Deals Of The Week Considers Merck’s New Play

Partnering its PD-1-specific antibody candidate with three other companies, Merck indicates a new era may have arrived for testing novel agents in combination. Also, NIH partners with 10 biopharmas to transform the discovery model and Myriad moves to buy Crescendo.

Right Dosing, Scheduling Key To Anticipating Resistance, Creating Synergistic Combos In Drug Development

The art of developing synergistic combinations of novel drugs that can win the race against resistance mutations was much discussed at the American Association for Cancer Research meeting in Chicago March 31 - April 4.

Beyond The Guidance: The Business Of Co-Development Combinations

FDA put together its well-received draft guidance on co-development of experimental drugs to be used in combination in less than a year, but even with regulators on board and the science burgeoning, the timeline for finding predictable ways for companies to actually collaborate on combining investigative cancer therapies looks to be much longer.

Related Content

Topics

UsernamePublicRestriction

Register

PS072186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel